AOB Pharma and Maruho enter into an agreement for AOB’s B244 for treatment of atopic dermatitis in Japan
The deal includes upfront payments, milestone payments and ongoing royalties
The deal includes upfront payments, milestone payments and ongoing royalties
Amarex Clinical Research guides its client to phase II of FDA trials
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
Results reinforce the well-established safety profile of Dupixent - the first-ever biologic medicine for atopic dermatitis currently approved for patients as young 6 years old
Developed by Pfizer, Abrocitinib has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO) in India
Astria will assume full cost and responsibility for the global development and commercialization of the licensed therapeutic program for all indications
Lebrikizumab is an investigational high-affinity and potent IL-13 inhibitor being studied in adult and adolescent patients
Bayer reported the highest market capitalization growth of 23.1% during Q1 2023
Label expansion for CIBINQO provides new systemic oral option for adolescents (12 to <18 years) with moderate-to-severe atopic dermatitis
Subscribe To Our Newsletter & Stay Updated